Dr. Jackson has a Ph.D. from Northwestern University where he studied molecular biology and biophysics. He completed his postdoctoral fellowship as a UNCF/Merck Fellow at the University of California San Fransciso (UCSF) in Dr. Douglas Hanahan's lab.
Dr. Jackson has over 20 years of experience working for large pharma (Pfizer and Novartis), biotech companies (MedImmune (AstraZeneca), Agensys (Astellas), Ambrx and Innovent Biologics) and non-profits (TB Alliance).
Dr. Jackson has expertise in developing small molecule inhibitors, bispecific T-cell engagers and antibody drug conjugates (ADCs), including bispecific ADCs. Dr. Jackson also has experience developing biologics that modulate tumor immune response.
He has led several successful teams, collaborations, published in top peer-reviewed journals, and authored book chapters.
Dr. Jackson has been invited to chair and present at international conferences.
He has progressed several anti-cancer drugs from early preclinical development, through IND, clinical development and BLA submission in the US, Europe, Australia and China.
Dr. Jackson is an avid pilot and scuba diver.